Equities analysts expect that American Renal Associates Holdings Inc (NYSE:ARA) will report sales of $215.01 million for the current fiscal quarter, Zacks Investment Research reports. Three analysts have provided estimates for American Renal Associates’ earnings, with the lowest sales estimate coming in at $210.84 million and the highest estimate coming in at $217.20 million. American Renal Associates reported sales of $194.38 million during the same quarter last year, which would suggest a positive year over year growth rate of 10.6%. The firm is scheduled to announce its next earnings results on Tuesday, March 5th.

On average, analysts expect that American Renal Associates will report full-year sales of $837.94 million for the current fiscal year, with estimates ranging from $833.71 million to $840.10 million. For the next fiscal year, analysts anticipate that the business will post sales of $891.20 million, with estimates ranging from $862.60 million to $910.00 million. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side research analysts that that provide coverage for American Renal Associates.

American Renal Associates (NYSE:ARA) last released its quarterly earnings data on Thursday, November 8th. The company reported $0.19 EPS for the quarter, beating the Zacks’ consensus estimate of $0.13 by $0.06. The company had revenue of $211.02 million during the quarter, compared to the consensus estimate of $217.15 million. American Renal Associates had a negative net margin of 1.81% and a positive return on equity of 22.30%. American Renal Associates’s quarterly revenue was up 12.4% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.19 EPS.

A number of research firms have commented on ARA. Zacks Investment Research downgraded shares of American Renal Associates from a “buy” rating to a “hold” rating in a report on Friday, January 25th. SunTrust Banks reiterated a “buy” rating and issued a $16.00 price objective on shares of American Renal Associates in a report on Wednesday, January 9th. Morgan Stanley began coverage on shares of American Renal Associates in a report on Friday, December 14th. They issued an “equal weight” rating for the company. Deutsche Bank began coverage on shares of American Renal Associates in a report on Thursday, January 3rd. They issued a “hold” rating and a $12.00 price objective for the company. Finally, ValuEngine downgraded shares of American Renal Associates from a “buy” rating to a “hold” rating in a report on Tuesday, December 18th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and four have issued a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and a consensus price target of $18.00.

ARA stock traded up $0.03 during mid-day trading on Friday, reaching $11.81. The company’s stock had a trading volume of 1,202 shares, compared to its average volume of 73,117. The company has a market cap of $383.05 million, a price-to-earnings ratio of 19.26, a PEG ratio of 3.19 and a beta of 2.13. The company has a current ratio of 1.03, a quick ratio of 1.00 and a debt-to-equity ratio of 5.48. American Renal Associates has a fifty-two week low of $11.09 and a fifty-two week high of $24.07.

Institutional investors have recently bought and sold shares of the company. MetLife Investment Advisors LLC purchased a new stake in shares of American Renal Associates in the 3rd quarter valued at approximately $230,000. Rhumbline Advisers grew its stake in shares of American Renal Associates by 47.5% in the 4th quarter. Rhumbline Advisers now owns 17,225 shares of the company’s stock valued at $198,000 after buying an additional 5,549 shares during the period. Engineers Gate Manager LP grew its stake in shares of American Renal Associates by 74.4% in the 3rd quarter. Engineers Gate Manager LP now owns 22,892 shares of the company’s stock valued at $496,000 after buying an additional 9,764 shares during the period. Adams Diversified Equity Fund Inc. purchased a new stake in shares of American Renal Associates in the 3rd quarter valued at approximately $559,000. Finally, Connor Clark & Lunn Investment Management Ltd. purchased a new stake in shares of American Renal Associates in the 3rd quarter valued at approximately $606,000. 94.42% of the stock is owned by institutional investors and hedge funds.

About American Renal Associates

American Renal Associates Holdings, Inc operates as a dialysis services provider in the United States. It operates dialysis clinics focusing on joint venture partnerships with physicians. The company offers kidney dialysis services to patients suffering from chronic kidney failure or end stage renal disease.

Featured Story: Momentum Investing

Get a free copy of the Zacks research report on American Renal Associates (ARA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for American Renal Associates (NYSE:ARA)

Receive News & Ratings for American Renal Associates Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for American Renal Associates and related companies with MarketBeat.com's FREE daily email newsletter.